1
|
Singh I, Gupta S, Deshmukh M, Gandhi M, Khopkar-Kale P. Serum Prolactin Levels as a Novel, Practical Marker for Predicting Malignant Diseases of the Breast. Cureus 2024; 16:e58375. [PMID: 38756317 PMCID: PMC11097618 DOI: 10.7759/cureus.58375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/15/2024] [Indexed: 05/18/2024] Open
Abstract
Background and objective Prolactin (PRL) has a high specificity toward breast cancer (BC), making it a valuable marker in both diagnosis and prognosis. In this study, we aimed to compare serum PRL levels between pre- and post-menopausal women with BC, as well as normal reference values. We also investigated the association of various risk factors with PRL levels in women with BC. Methods The study involved adult women diagnosed with BC based on clinical features and tissue histopathology receiving treatment at a tertiary care center in Pune, India. General and demographic information, anthropometric measurements (height, weight, and BMI), menstrual status (age at menarche and menopausal state), clinical presentation (signs and symptoms), duration of symptoms, and parity were recorded by using a pre-tested proforma based on hospital records or in-person interviews. Serum PRL was measured by the RIA method (sandwich assay). Results A total of 67 women (average age: 47.5 ± 11.8 years; 33 of them post-menopausal) with BC were included in the study. The participants had an average BMI of 24.9 ± 3.5 kg/m2, and 26 (39%) of them were overweight. The majority of women had BC stage IIA disease, involvement of the right side or upper outer quadrant, and had attained menarche after 14 years of age; 47 women had a BC duration of >3 months. Seven women were nulliparous, and the remaining had given birth to their first child before the age of 26 years. The average serum PRL level among the participants was 9.27 ± 7.62 ng/mL, with higher levels found in post-menopausal women compared to pre-menopausal women (11.08 vs. 7.51 ng/mL, respectively; p=0.08). Women with a higher stage and greater duration of disease had significantly higher serum PRL levels (p<0.001 for both). When compared with reference values, pre-menopausal women showed significantly lower (6.25 vs. 10.9, respectively; p=0.001) and post-menopausal women showed significantly higher (8.55 vs. 5.95; p=0.004) serum PRL levels. A positive correlation was found between serum PRL and age at the time of birth of the first child (p=0.068). Conclusions Based on our findings, PRL is an important hormone in the development of BC in women. Therapeutic modulation of PRL may be a realistic and novel approach to curing human BC, either administered alone or in combination with conventional treatments.
Collapse
Affiliation(s)
| | - Samir Gupta
- Surgical Oncology, Dr. D. Y. Patil Medical College and Hospital, Pune, IND
| | - Madhura Deshmukh
- Central Research Facility, Dr. D. Y. Patil Medical College and Hospital, Pune, IND
| | - Madhura Gandhi
- Central Research Facility, Dr. D. Y. Patil Medical College and Hospital, Pune, IND
| | | |
Collapse
|
2
|
Cisoń-Jurek S, Czajka-Francuz P, Francuz T, Owczarek AJ, Szymczak B, Wojnar J, Chudek J. The Value of Prolactin, a Panel of Cytokines, and the Soluble Human Epidermal Growth Factor Receptor 2 in the Prediction of Rapid Progression and Shorter Survival during Palliative Chemotherapy of Colorectal Cancer Patients. Biomedicines 2023; 11:2014. [PMID: 37509653 PMCID: PMC10377747 DOI: 10.3390/biomedicines11072014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 07/03/2023] [Accepted: 07/11/2023] [Indexed: 07/30/2023] Open
Abstract
The prediction of colorectal cancer (CRC) response to palliative chemotherapy (CTH) is still difficult. Patients at a higher risk of progression may benefit from more aggressive treatment. This study assessed the predictive value of prolactin (PRL) and a panel of cytokines, chemokines, and growth factors for the risk of rapid progression in CRC patients starting palliative CTH. This study included 51 CRC patients initiating palliative CTH with up to 5-year follow-up, divided into rapid and non-rapid progressors. Serum samples were collected before CTH for assessment of a large panel of cytokines, chemokines, growth factors, and PRL via a multiplex method. Rapid progressors (N = 19) were characterized by increased baseline values of IL-8 and IP10 but decreased PRL levels. In addition, PRL below 18.2 ng/mL was a strong predictor of weight loss during CTH. Grade 3 (HR = 2.97; 95%CI: 1.48-5.98) and PRL level (HR = 0.96; 95%CI: 0.91-1.01) were independent risk factors of progression. We showed that CRC rapid progressors are characterized by decreased baseline PRL levels. In addition, increased baseline levels of IP-10, sHER-2, IL-6, and IL-8 may be associated with longer survival; however, larger studies are needed to confirm their predictive role in CRC patients.
Collapse
Affiliation(s)
- Sylwia Cisoń-Jurek
- Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Str. Reymonta 8, 40-027 Katowice, Poland
| | - Paulina Czajka-Francuz
- Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Str. Reymonta 8, 40-027 Katowice, Poland
| | - Tomasz Francuz
- Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Str. Medyków 18, 40-752 Katowice, Poland
| | - Aleksander J Owczarek
- Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Silesian Medical University, Str. Medyków 18, 40-752 Katowice, Poland
| | - Bożena Szymczak
- Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Str. Reymonta 8, 40-027 Katowice, Poland
| | - Jerzy Wojnar
- Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Str. Reymonta 8, 40-027 Katowice, Poland
| | - Jerzy Chudek
- Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Str. Reymonta 8, 40-027 Katowice, Poland
| |
Collapse
|
3
|
Gabrielson M, Ubhayasekera K, Ek B, Andersson Franko M, Eriksson M, Czene K, Bergquist J, Hall P. Inclusion of Plasma Prolactin Levels in Current Risk Prediction Models of Premenopausal and Postmenopausal Breast Cancer. JNCI Cancer Spectr 2018; 2:pky055. [PMID: 31360875 PMCID: PMC6649752 DOI: 10.1093/jncics/pky055] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Revised: 08/31/2018] [Accepted: 10/08/2018] [Indexed: 01/07/2023] Open
Abstract
Background Circulating plasma prolactin is associated with breast cancer risk and may improve our ability to identify high-risk women. Mammographic density is a strong risk factor for breast cancer, but the association with prolactin is unclear. We studied the association between breast cancer, established breast cancer risk factors and plasma prolactin, and improvement of risk prediction by adding prolactin. Methods We conducted a nested case-control study including 721 breast cancer patients and 1400 age-matched controls. Plasma prolactin levels were assayed using immunoassay and mammographic density measured by STRATUS. Odds ratios (ORs) were calculated by multivariable adjusted logistic regression, and improvement in the area under the curve for the risk of breast cancer by adding prolactin to established risk models. Statistical tests were two-sided. Results In multivariable adjusted analyses, prolactin was associated with risk of premenopausal (OR, top vs bottom quintile = 1.9; 1.88 (95% confidence interval [CI] = 1.08 to 3.26) but not with postmenopausal breast cancer. In postmenopausal cases prolactin increased by 10.6% per cBIRADS category (Ptrend = .03). In combined analyses of prolactin and mammographic density, ORs for women in the highest vs lowest tertile of both was 3.2 (95% CI = 1.3 to 7.7) for premenopausal women and 2.44 (95% CI = 1.44 to 4.14) for postmenopausal women. Adding prolactin to current risk models improved the area under the curve of the Gail model (+2.4 units, P = .02), Tyrer-Cuzick model (+3.8, P = .02), and the CAD2Y model (+1.7, P = .008) in premenopausal women. Conclusion Circulating plasma prolactin and mammographic density appear independently associated with breast cancer risk among premenopausal women, and prolactin may improve risk prediction by current risk models.
Collapse
Affiliation(s)
- Marike Gabrielson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Kumari Ubhayasekera
- Analytical Chemistry and Neurochemistry, Department of Chemistry, Uppsala University, Uppsala, Sweden
| | - Bo Ek
- Analytical Chemistry and Neurochemistry, Department of Chemistry, Uppsala University, Uppsala, Sweden
| | - Mikael Andersson Franko
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Mikael Eriksson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Kamila Czene
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Jonas Bergquist
- Analytical Chemistry and Neurochemistry, Department of Chemistry, Uppsala University, Uppsala, Sweden
| | - Per Hall
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.,Department of Oncology, South General Hospital, Stockholm, Sweden
| |
Collapse
|
4
|
Mandalà M, Lissoni P, Ardizzoia A, Barni S, Rovelli F, Confalonieri G, Malugani F, Moro C, Fumagalli G, Giani L, Tancini G. Endocrinological Study of the Dopaminergic Regulation of Prolactin Release in Metastatic Breast Cancer. TUMORI JOURNAL 2018; 85:494-7. [PMID: 10774572 DOI: 10.1177/030089169908500613] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and Background Prolactin (PRL) may be a growth factor for breast cancer. Abnormally high levels of PRL have been proven to be associated with a poor prognosis in metastatic breast cancer. However, most studies have been limited to the evaluation of basal levels of PRL rather than its response to the classical endocrine dynamic tests. This study was performed to analyse the dynamic secretion of PRL under stimulatory and inhibitory tests in metastatic breast cancer. Methods The study included 10 untreated metastatic breast cancer women, who were evaluated after the classical stimulatory and inhibitory tests for PRL secretion with the antidopaminergic agent Metoclopramide (10 mg iv as a bolus) and with L-dopa, respectively. Serum levels of PRL were measured by RIA before and at subsequent intervals after drug administration. PRL levels were considered to be elevated when they were higher than 25 ng/ml. Results Abnormally high basal levels of PRL were seen in 6/10 patients. L-dopa was unable to inhibit PRL secretion, whose mean concentrations paradoxically significantly increased in response to L-dopa, with values comparable to those observed after the classical stimulatory test with metoclopramide. Conclusions This study confirm the existence of hyperprolactinemia associated with metastatic breast cancer. In addition, by showing a paradoxical rise of PRL in response to L-dopa, which inhibits PRL secretion in physiological conditions, this study would suggest that breast cancer-related hyperprolactinemia may depend at least in part on endogenous disease-related neuroendocrine alterations.
Collapse
Affiliation(s)
- M Mandalà
- Divisione di Radioterapia Oncologica, Ospedale San Gerardo, Monza, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Lissoni P, Bignami A, Frontini L, Manganini V, Dapretto E, Gardani G, Viganò P, Strada G. Possible Involvement of Prolactin in Endocrine-Resistant Metastatic Prostate Cancer. Int J Biol Markers 2018. [DOI: 10.1177/172460080502000207] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The hormone resistance of prostate cancer has been proved to depend at least in part on enhanced neuroendocrine activity and the resultant increase in blood concentrations of chromogranin A. Other experimental observations have suggested the involvement of prolactin (PRL), which appears to be a potential growth factor for prostate cancer. Abnormally high levels of PRL have been detected in metastatic prostate cancer, but the clinical significance of this finding has still to be clarified. In an attempt to explain the prognostic significance of serum PRL levels in prostate cancer, in this preliminary study we have analyzed the PRL levels in a group of metastatic prostate cancer patients with hormone-dependent or hormone-resistant cancer. The study included 50 patients with metastatic prostate cancer, 15 of whom had hormone-resistant tumors. The serum levels of PRL were measured by the RIA method. Abnormally high concentrations of PRL were found in 11/50 (22%) patients. Moreover, the percent of patients with cancer-related hyperprolactinemia was significantly higher in the hormone-resistant group than in the hormone-dependent group (8/15 vs 3/35, p<0.01). This study confirms the possible existence of a hyperprolactinemic state in metastatic prostate cancer, as previously reported by other authors. Moreover, it appears to demonstrate that the occurrence of hyperprolactinemia is more frequent in hormone-resistant neoplasms, suggesting the possible involvement of PRL in hormone independence. Further studies concomitantly evaluating PRL and chromogranin A blood concentrations will be necessary to establish whether the hyperprolactinemia precedes and promotes the onset of hormone resistance in prostate cancer, or whether it is simply a consequence of the hormone independence.
Collapse
Affiliation(s)
- P. Lissoni
- Division of Radiation Oncology, San Gerardo Hospital, Monza, Milan - Italy
| | - A. Bignami
- Division of Radiation Oncology, San Gerardo Hospital, Monza, Milan - Italy
| | - L. Frontini
- Division of Radiation Oncology, San Gerardo Hospital, Monza, Milan - Italy
| | - V. Manganini
- Division of Urology, San Gerardo Hospital, Monza, Milan - Italy
| | - E. Dapretto
- Division of Radiation Oncology, San Gerardo Hospital, Monza, Milan - Italy
| | - G.S. Gardani
- Division of Radiation Oncology, San Gerardo Hospital, Monza, Milan - Italy
| | - P. Viganò
- Division of Urology, San Gerardo Hospital, Monza, Milan - Italy
| | - G. Strada
- Division of Urology, San Gerardo Hospital, Monza, Milan - Italy
| |
Collapse
|
6
|
What Is Breast in the Bone? Int J Mol Sci 2016; 17:ijms17101764. [PMID: 27782069 PMCID: PMC5085788 DOI: 10.3390/ijms17101764] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Revised: 10/11/2016] [Accepted: 10/14/2016] [Indexed: 12/17/2022] Open
Abstract
The normal developmental program that prolactin generates in the mammary gland is usurped in the cancerous process and can be used out of its normal cellular context at a site of secondary metastasis. Prolactin is a pleiotropic peptide hormone and cytokine that is secreted from the pituitary gland, as well as from normal and cancerous breast cells. Experimental and epidemiologic data suggest that prolactin is associated with mammary gland development, and also the increased risk of breast tumors and metastatic disease in postmenopausal women. Breast cancer spreads to the bone in approximately 70% of cases with advanced breast cancer. Despite treatment, new bone metastases will still occur in 30%–50% of patients. Only 20% of patients with bone metastases survive five years after the diagnosis of bone metastasis. The breast cancer cells in the bone microenvironment release soluble factors that engage osteoclasts and/or osteoblasts and result in bone breakdown. The breakdown of the bone matrix, in turn, enhances the proliferation of the cancer cells, creating a vicious cycle. Recently, it was shown that prolactin accelerated the breast cancer cell-mediated osteoclast differentiation and bone breakdown by the regulation of breast cancer-secreted proteins. Interestingly, prolactin has the potential to affect multiple proteins that are involved in both breast development and likely bone metastasis, as well. Prolactin has normal bone homeostatic roles and, combined with the natural “recycling” of proteins in different tissues that can be used for breast development and function, or in bone function, increases the impact of prolactin signaling in breast cancer bone metastases. Thus, this review will focus on the role of prolactin in breast development, bone homeostasis and in breast cancer to bone metastases, covering the molecular aspects of the vicious cycle.
Collapse
|
7
|
Hammer A, Diakonova M. Prolactin-induced PAK1 tyrosyl phosphorylation promotes FAK dephosphorylation, breast cancer cell motility, invasion and metastasis. BMC Cell Biol 2016; 17:31. [PMID: 27542844 PMCID: PMC4992334 DOI: 10.1186/s12860-016-0109-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2016] [Accepted: 08/04/2016] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The serine/threonine kinase PAK1 is an important regulator of cell motility. Both PAK1 and the hormone/cytokine prolactin (PRL) have been implicated in breast cancer cell motility, however, the exact mechanisms guiding PRL/PAK1 signaling in breast cancer cells have not been fully elucidated. Our lab has previously demonstrated that PRL-activated tyrosine kinase JAK2 phosphorylates PAK1 on tyrosines 153, 201, and 285, and that tyrosyl phosphorylated PAK1 (pTyr-PAK1) augments migration and invasion of breast cancer cells. RESULTS Here we further investigate the mechanisms by which pTyr-PAK1 enhances breast cancer cell motility in response to PRL. We demonstrate a distinct reduction in PRL-induced FAK auto-phosphorylation in T47D and TMX2-28 breast cancer cells overexpressing wild-type PAK1 (PAK1 WT) when compared to cells overexpressing either GFP or phospho-tyrosine-deficient mutant PAK1 (PAK1 Y3F). Furthermore, pTyr-PAK1 phosphorylates MEK1 on Ser298 resulting in subsequent ERK1/2 activation. PRL-induced FAK auto-phosphorylation is rescued in PAK1 WT cells by inhibiting tyrosine phosphatases and tyrosine phosphatase inhibition abrogates cell motility and invasion in response to PRL. siRNA-mediated knockdown of the tyrosine phosphatase PTP-PEST rescues FAK auto-phosphorylation in PAK1 WT cells and reduces both cell motility and invasion. Finally, we provide evidence that PRL-induced pTyr-PAK1 stimulates tumor cell metastasis in vivo. CONCLUSION These data provide insight into the mechanisms guiding PRL-mediated breast cancer cell motility and invasion and highlight a significant role for pTyr-PAK1 in breast cancer metastasis.
Collapse
Affiliation(s)
- Alan Hammer
- Department of Biological Sciences, University of Toledo, 2801 W. Bancroft Street, Toledo, 43606-3390, OH, USA
| | - Maria Diakonova
- Department of Biological Sciences, University of Toledo, 2801 W. Bancroft Street, Toledo, 43606-3390, OH, USA.
| |
Collapse
|
8
|
Harrington KM, Clevenger CV. Identification of NEK3 Kinase Threonine 165 as a Novel Regulatory Phosphorylation Site That Modulates Focal Adhesion Remodeling Necessary for Breast Cancer Cell Migration. J Biol Chem 2016; 291:21388-21406. [PMID: 27489110 PMCID: PMC5076809 DOI: 10.1074/jbc.m116.726190] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Revised: 07/27/2016] [Indexed: 01/09/2023] Open
Abstract
Accumulating evidence supports a role for prolactin (PRL) in the development and progression of human breast cancer. Although PRL is an established chemoattractant for breast cancer cells, the precise molecular mechanisms of how PRL regulates breast cancer cell motility and invasion are not fully understood. PRL activates the serine/threonine kinase NEK3, which was reported to enhance breast cancer cell migration, invasion, and the actin cytoskeletal reorganization necessary for these processes. However, the specific mechanisms of NEK3 activation in response to PRL signaling have not been defined. In this report, a novel PRL-inducible regulatory phosphorylation site within the activation segment of NEK3, threonine 165 (Thr-165), was identified. Phosphorylation at NEK3 Thr-165 was found to be dependent on activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway using both pharmacological inhibition and siRNA-mediated knockdown approaches. Strikingly, inhibition of phosphorylation at NEK3 Thr-165 by expression of a phospho-deficient mutant (NEK3-T165V) resulted in increased focal adhesion size, formation of zyxin-positive focal adhesions, and reorganization of the actin cytoskeleton into stress fibers. Concordantly, NEK3-T165V cells exhibited migratory defects. Together, these data support a modulatory role for phosphorylation at NEK3 Thr-165 in focal adhesion maturation and/or turnover to promote breast cancer cell migration.
Collapse
Affiliation(s)
- Katherine M Harrington
- From the Department of Pathology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611 and
| | - Charles V Clevenger
- the Department of Pathology, Virginia Commonwealth University, Richmond, Virginia 23298
| |
Collapse
|
9
|
Sutherland A, Forsyth A, Cong Y, Grant L, Juan TH, Lee JK, Klimowicz A, Petrillo SK, Hu J, Chan A, Boutillon F, Goffin V, Egan C, Tang PA, Cai L, Morris D, Magliocco A, Shemanko CS. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation. J Natl Cancer Inst 2015; 108:djv338. [PMID: 26586670 DOI: 10.1093/jnci/djv338] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Accepted: 10/15/2015] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Metastasis to the bone is a deleterious aspect of breast cancer and is a preferred site that results in bone loss. Hormones such as prolactin (PRL) have not yet been studied for their role in modulating the secondary tumor bone microenvironment. METHODS We used quantitative immunohistochemistry with 134 samples of human primary breast cancer and 17 matched primary breast cancers and bone metastases. A Cox proportional hazards regression model was fitted to evaluate the associations between high prolactin receptor (PRLR) expression and time to bone metastasis, adjusting for estrogen receptor status, lymph node status, and chemotherapy status. We assessed osteoclast differentiation, osteoclast size, and measured pit formation in dentine slices. Statistical tests were two-sided. RESULTS High PRLR expression in the primary breast tumor was associated with a shorter time to metastasis that includes bone (PRLRAQUA Max-per 100 unit hazard ratio = 1.04, 95% confidence interval = 1.00 to 1.07, P = .03). We observed the PRLR in rare samples of bone metastases and matched primary breast cancer. PRL treatment of breast cancer cells induced osteoclast differentiation and bone lysis via secreted factors and was abrogated by a PRLR antagonist (delta1-9-G129R-hPRL). We demonstrated that sonic hedgehog is a PRL-regulated cytokine in breast cancer cells and part of the mechanism that induces osteoclast differentiation. CONCLUSIONS Our evidence indicates that PRL-PRLR can escalate the impact of breast cancer on bone metastasis and that the presence of the PRLR in the tumor microenvironment of breast cancer bone metastasis has the potential to modulate the microenvironment to induce lytic osteoclast formation.
Collapse
Affiliation(s)
- Ashley Sutherland
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Amanda Forsyth
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Yingying Cong
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Laurel Grant
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Tzu-Hua Juan
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Jae K Lee
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Alexander Klimowicz
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Stephanie K Petrillo
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Jinghui Hu
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Angela Chan
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Florence Boutillon
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Vincent Goffin
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Cay Egan
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Patricia A Tang
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Li Cai
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Don Morris
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Anthony Magliocco
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Carrie S Shemanko
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| |
Collapse
|
10
|
O'Leary KA, Rugowski DE, Sullivan R, Schuler LA. Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas. Oncogene 2013; 33:3075-82. [PMID: 23873024 DOI: 10.1038/onc.2013.278] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2013] [Revised: 04/13/2013] [Accepted: 05/16/2013] [Indexed: 01/05/2023]
Abstract
TP53 is one of the most commonly mutated genes in cancer. In breast cancer, it is mutated in about 40% of primary clinical tumors and is associated with poor survival. The mammotrophic hormone, prolactin (PRL), and/or its receptor are also expressed in many breast cancers, and accumulating epidemiologic data link PRL to breast cancer development and progression. Like TP53 mutations, evidence for PRL activity is evident across several molecular cancer subtypes, and elevated PRL expression and loss of p53 have been observed in some of the same clinical tumors. In order to examine the interaction of these factors, we used genetically modified mouse models of mammary-specific p53 loss and local overexpression of PRL. We demonstrated that mammary PRL decreased the latency of tumors in the absence of p53, and increased the proportion of triple-negative claudin-low carcinomas, which display similarities to human clinical metaplastic carcinomas. Moreover, PRL/p53(-/-) carcinomas displayed higher rates of proliferation and more aggressive behavior. Transcripts associated with cell cycle progression, invasion and stromal reactivity were differentially expressed in carcinomas that developed in the presence of elevated PRL. PRL/p53(-/-) carcinomas also exhibited selectively altered expression of activating protein-1 components, including higher levels of c-Jun and FosL1, which can drive transcription of many of these genes and the epithelial-mesenchymal transition. The ability of PRL to promote claudin-low carcinomas demonstrates that PRL can influence this subset of triple-negative breast cancers, which may have been obscured by the relative infrequency of this cancer subtype. Our findings suggest novel therapeutic approaches, and provide a preclinical model to develop possible agents.
Collapse
Affiliation(s)
- K A O'Leary
- Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA
| | - D E Rugowski
- Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA
| | - R Sullivan
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI, USA
| | - L A Schuler
- 1] Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA [2] University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI, USA
| |
Collapse
|
11
|
Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf 2010; 20:131-7. [PMID: 21254283 DOI: 10.1002/pds.2064] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2010] [Revised: 08/23/2010] [Accepted: 09/13/2010] [Indexed: 01/06/2023]
Abstract
PURPOSE The aim of this study was to assess the post-diagnosis use of antidepressants and non-steroidal anti-inflammatory drugs (NSAIDs) in relation to all-cause, breast cancer, and cardiovascular disease (CVD) mortality among long-term breast cancer survivors. METHODS A cohort of 3058 breast cancer survivors, who previously participated in a series of case-control studies diagnosed between 1988 and 1999 in Wisconsin. Cancer survivors completed a self-administered mailed follow-up questionnaire in 1998-2001 that addressed use of medications post-diagnosis, including antidepressants and NSAIDs. Vital status information was obtained through the National Death Index through 31 December 2006. We used multivariable Cox proportional hazards modeling to estimate hazard ratios and 95% confidence intervals (CI). RESULTS We identified 463 deaths due to all-causes, 163 due to breast cancer, and 93 due to CVD during follow-up. Among women who had used any antidepressant after a breast cancer diagnosis, there was an increased risk of all-cause (adjusted HR=1.50, 95%CI: 1.12-2.02) and CVD mortality (HR=2.42, 95%CI: 1.21-4.83), but not breast cancer mortality (HR=0.93, 95%CI: 0.55-1.56). The use of NSAIDs after diagnosis was not associated with all-cause (HR=0.87, 95%CI: 0.69-1.18), breast cancer mortality (HR=0.69, 95%CI: 0.44-1.10), or CVD (HR=0.97, 95%CI: 0.57-1.65). CONCLUSIONS The use of antidepressants or NSAIDS was not related to breast cancer mortality in long-term breast cancer survivors. In these women, however, antidepressants may increase the risk of all-cause mortality.
Collapse
Affiliation(s)
- Karen J Wernli
- Program in Cancer Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98101, USA.
| | | | | | | |
Collapse
|
12
|
Tworoger SS, Hankinson SE. Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia 2008; 13:41-53. [PMID: 18246319 DOI: 10.1007/s10911-008-9063-y] [Citation(s) in RCA: 101] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2007] [Accepted: 01/02/2008] [Indexed: 10/22/2022] Open
Abstract
A number of epidemiologic studies of prolactin and breast cancer etiology have recently become available. Retrospective case-control studies have suggested a modest positive or null relationship between circulating prolactin concentrations and risk of breast cancer. However these studies are limited by small sample sizes and the collection of blood after case diagnosis. Several large prospective studies, in which blood was collected prior to diagnosis, have observed modest positive associations between prolactin and risk. In a pooled analysis of approximately 80% of the world's prospective data, the relative risk (RR) comparing women in the top vs bottom quartile of prolactin levels was 1.3 (95% confidence interval (CI): 1.1, 1.6, p-trend = 0.002). The results were similar for premenopausal and postmenopausal women. Most notably, high prolactin levels were associated with a 60% increased risk of estrogen receptor (ER) positive tumors, but not with ER negative tumors. Limited genetic data suggest a role of polymorphisms in the prolactin and prolactin receptor genes in risk of breast cancer. Studies of survival have suggested that high pretreatment prolactin levels were associated with treatment failure, earlier recurrence, and worse overall survival. Parity and certain medications are the only confirmed factors associated with prolactin levels in women. Overall, epidemiologic data suggest that prolactin is involved in breast cancer etiology. Further research to better elucidate these associations and their underlying mechanisms is warranted.
Collapse
Affiliation(s)
- Shelley S Tworoger
- Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
| | | |
Collapse
|
13
|
Miller SL, Antico G, Raghunath PN, Tomaszewski JE, Clevenger CV. Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene 2007; 26:4668-78. [PMID: 17297458 DOI: 10.1038/sj.onc.1210264] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Prolactin (PRL) stimulates the cytoskeletal re-organization and motility of breast cancer cells. During PRL receptor signaling, Vav2 becomes phosphorylated and activated, an event regulated by the serine/threonine kinase Nek3. Given the regulatory role of Vav2, the function of Nek3 in PRL-mediated motility and invasion was examined. Overexpression of Nek3 in Chinese hamster ovary transfectants potentiated cytoskeletal re-organization in response to PRL. In contrast, downregulation of Nek3 expression by small-interfering RNA (siRNA) attenuated PRL-mediated cytoskeletal reorganization, activation of GTPase Rac1, cell migration and invasion of T47D cells. In addition, PRL stimulation induced an interaction between Nek3 and paxillin and significantly increased paxillin serine phosphorylation, whereas Nek3 siRNA-transfected cells showed a marked reduction in paxillin phosphorylation. Analysis of breast tissue microarrays also demonstrated a significant up-regulation of Nek3 expression in malignant versus normal specimens. These data suggest that Nek3 contributes to PRL-mediated breast cancer motility through mechanisms involving Rac1 activation and paxillin phosphorylation.
Collapse
Affiliation(s)
- S L Miller
- Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | | | | | | |
Collapse
|
14
|
Manfroid I, Van de Weerdt C, Baudhuin A, Martial JA, Muller M. EGF stimulates Pit-1 independent transcription of the human prolactin pituitary promoter in human breast cancer SK-BR-3 cells through its proximal AP-1 response element. Mol Cell Endocrinol 2005; 229:127-39. [PMID: 15607537 DOI: 10.1016/j.mce.2004.08.009] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2004] [Revised: 08/19/2004] [Accepted: 08/20/2004] [Indexed: 11/26/2022]
Abstract
Normal and neoplastic human mammary gland cells are targets for the proliferative action of prolactin. These cells also synthesize prolactin, thereby inducing an autocrine/paracrine proliferative loop. We present the first extensive analysis of the transcriptional regulation of the human prolactin gene (hPRL) in human mammary tumor cells, SK-BR-3. We show that the pituitary promoter is functional in these cells in the absence of the pituitary-specific factor Pit-1. Expression of exogenous Pit-1 or epidermal growth factor (EGF) treatment stimulates the transfected hPRL pituitary promoter and the endogenous hPRL expression. EGF stimulation is mediated by increased synthesis of c-fos and c-jun, resulting in AP-1 binding to the proximal hPRL pituitary promoter. This regulation involves the EGF receptor, possibly ErbB2 that is highly expressed in SK-BR-3 cells, and a PI3K/JNK pathway. The stimulation of hPRL gene transcription by EGF in mammary cells may include hPRL in a complex regulatory network controlling growth of human mammary cells.
Collapse
Affiliation(s)
- Isabelle Manfroid
- Laboratoire de Biologie Moléculaire et de Génie Génétique, Institut de Chimie B6, Université de Liège, B-4000 Sart-Tilman, Belgium
| | | | | | | | | |
Collapse
|
15
|
Perumal BG, Moodley J, Pegoraro RJ. Prolactin as a tumour marker in cancer of the cervix. J OBSTET GYNAECOL 2004; 18:260-2. [PMID: 15512073 DOI: 10.1080/01443619867452] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The aim of this study was to determine the possible usefulness of prolactin as a tumour marker in cancer of the cervix. Serum prolactin levels were measured using an enzyme linked immunosorbent assay in 105 women divided into malignant, pre-malignant and control groups. Elevated levels of prolactin were found in 42.9% of patients with malignant disease, 22.9% of controls and 14.2% of individuals with premalignant disease. The differences were not statistically significant. Although prolactin levels were found to be elevated in some patients with malignant disease of the cervix, further studies are needed to establish whether this is of clinical significance.
Collapse
Affiliation(s)
- B G Perumal
- MRC/UN Pregnancy Hypertension Research Unit and Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Natal, Durban, South Africa
| | | | | |
Collapse
|
16
|
Sancak B, Coskun U, Gunel N, Onuk E, Cihan A, Karamercan A, Yildirim Y, Ozkan S. No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery. Intern Med J 2004; 34:310-5. [PMID: 15228391 DOI: 10.1111/j.1444-0903.2004.00591.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Angiogenesis is essential for tumour growth and metastasis. Vascular endothelial growth factor (VEGF) has been suggested as the major angio-genic factor in breast carcinoma. Both insulin-like growth factor-I (IGF-I) and prolactin are involved in the progression of breast cancer at least partly by stimulating angiogenesis. AIM The aim of the present study was to investigate the association between serum IGF-I, VEGF and prolactin levels and clinicopathological characteristics of breast carcinoma. METHODS Serum IGF-I, VEGF and prolactin levels were measured in breast cancer patients and controls and these levels were compared with well-known clinicopathological characteristics of breast carcinoma, including tumour size, axillary lymph node and oestrogen/progesterone receptor status, tumour grade and disease stage. RESULTS Serum prolactin, VEGF and IGF-I levels were found to be similar in breast cancer patients and control subjects (P > 0.05). When the patients were divided into groups according to their tumour size, axillary lymph node status, tumour grade, oestrogen/progesterone receptor status and disease stage, no significant differences in serum prolactin, VEGF and IGF-I levels were found among the groups (P > 0.05). CONCLUSIONS The present study failed to demonstrate an association between serum levels of VEGF, IGF-I and prolactin and well-known clinicopathological characteristics of breast carcinoma.
Collapse
Affiliation(s)
- B Sancak
- Department of Biochemistry, Gazi University Medical School, Ankara, Turkey
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Turner-Cobb JM. Psychological and neuroendocrine correlates of disease progression. INTERNATIONAL REVIEW OF NEUROBIOLOGY 2003; 52:353-81. [PMID: 12498111 DOI: 10.1016/s0074-7742(02)52016-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Affiliation(s)
- Julie M Turner-Cobb
- Department of Psychology, University of Kent at Canterbury, Canterbury, Kent CT2 7NP, United Kingdom
| |
Collapse
|
18
|
Abstract
The contribution of prolactin (PRL) to the pathogenesis and progression of human breast cancer at the cellular, transgenic, and epidemiological levels is increasingly appreciated. Acting at the endocrine and autocrine/paracrine levels, PRL functions to stimulate the growth and motility of human breast cancer cells. The actions of this ligand are mediated by at least six recognized PRL receptor isoforms found on, or secreted by, human breast epithelium. The PRL/PRL receptor complex associates with and activates several signaling networks that are shared with other members of the cytokine receptor superfamily. Coupled with the recently identified intranuclear function of PRL, these networks are integrated into the in vitro and in vivo actions induced by ligand. These findings indicate that antagonists of PRL/PRL receptor interaction or PRL receptor-associated signal transduction may be of considerable utility in the treatment of human breast cancer.
Collapse
Key Words
- cis, cytokine-inducible inhibitor of signaling
- cypb, cyclophilin b
- ecd, extracellular domain
- egf, epidermal growth factor
- ghr, gh receptor
- hprlr, human prlr
- icd, intracellular domain
- jak, janus kinase 2
- jnk, c-jun n-terminal kinase
- pias, peptide inhibitor of activated stat
- pi3k, phosphatidylinositol 3′-kinase
- prl, prolactin
- ptdins, phosphatidylinositol
- prlbp, prl binding protein
- prlr, prl receptor
- shp-2, sh2-containing protein tyrosine phosphatase
- socs, suppressor of cytokine signaling
- stat, signal transducer and activator of transcription
Collapse
Affiliation(s)
- Charles V Clevenger
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
| | | | | | | |
Collapse
|
19
|
Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, Chikhlikar PR, Trivedi TI. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 2000; 26:540-7. [PMID: 11034803 DOI: 10.1053/ejso.2000.0943] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
AIMS The aim of this study was to evaluate the prognostic value of pre-operative prolactin (PRL) in conjunction with established prognosticators, and the risk of disease relapse in patients with early and advanced breast cancer. To confirm the hypothesis that PRL is produced by breast tumours molecular analysis of PRL, using immunohistochemistry, mRNA by RT-PCR and direct sequencing, was performed. Furthermore, presence of prolactin receptors (PRLR) was evaluated by immunohistochemical localization in these patients. METHODS In 111 breast cancer patients, pre-operative PRL was determined by an immunoradiometric assay (IRMA) method. Immunohistochemical localization of PRL (IHL-PRL) and PRLR was performed on formalin-fixed, paraffin-embedded tissue sections. Expression of PRL mRNA was carried out by reverse transcriptase polymerase chain reaction (RT-PCR). RT-PCR PRL amplimer was sequenced and compared with human pituitary PRL amplimer. RESULTS Fifty-eight per cent (64/111) of the patients had hyperprolactinaemia (PRL520.0 ng/ml). With increasing tumour size, a higher incidence of hyperprolactinaemia was noted which was statistically significant (r=0.34, P=0.0001). In stage III patients, and in node positive patients, the incidence of hyperprolactinaemia was significantly higher compared to their respective counterparts (stage II vs stage III, r=0.37, P=0.00006; node negative vs node positive, r=0.30, P=0.001). Hyperprolactinaemic patients had a significantly higher risk of developing recurrent/metastatic disease and a higher mortality risk as compared to patients with PRL <20.0 ng/ml. The multivariate survival analysis indicated that apart from disease stage, prognosis of patients with pre-operative hyperprolactinaemia was poorer than that of patients with PRL <20.0 ng/ml. Seventy-eight per cent (87/111) of the tumours showed positive immunoreactivity with PRL antibody indicating that PRL, or a similar molecule, is produced ectopically by breast tumours. PRL mRNA expression using RT-PCR confirmed the de novo synthesis of PRL. PRL mRNA expression was seen in 52% (33/63) of tumours. Sequence analysis of the 234 bp PRL amplimer revealed that the sequence was homologous to the sequence of exon 5 of human pituitary PRL mRNA. Furthermore, PRLR were present in 80% of tumours detected by immunohistochemical localization. A significant positive correlation was noted between IHL-PRL and PRLR (r=0.26, P=0.006). CONCLUSIONS This multifaceted study of PRL suggests that breast cancer cells produce PRL and that this ectopically produced PRL may act as a major local growth promoter via autocrine and paracrine mechanisms. It may provide new insights into endocrine treatment of breast cancer.
Collapse
Affiliation(s)
- J M Bhatavdekar
- The Gujarat Cancer and Research Institute, NCH Compound, Asarwa, Ahmedabad, 380 016, India
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Chikhlikar PR, Ghosh N, Trivedi TI. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Ann Surg Oncol 2000; 7:305-11. [PMID: 10819372 DOI: 10.1007/s10434-000-0305-5] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND The aim was to investigate the expression of a panel of biomarkers such as prolactin (PRL), p53, Bcl-2, c-erb B2, Ki-67, CD44, and factor VIII-related antigen (FVIII-RA) in primary tumors of stage II and stage III breast cancer and its correlation with disease prognostication. METHODS The streptavidin-biotin peroxidase complex technique was used for the detection of these antigens. Cytoplasmic staining pattern was observed for PRL, Bcl-2, and Ki-67. Staining pattern for p53 was nuclear. Membranous and/or cytoplasmic staining was noted for c-erb B2 and CD44. Microvessel staining was noted for FVIII-RA. RESULTS Of the 93 primary breast tumors analyzed, positivity for PRL was noted in 82%, for p53 in 56%, for Bcl-2 in 73%, for c-erb B2 in 68%, and for Ki-67 and CD44 in 78% each. The microvessel count (MVC) for FVIII-RA ranged from 0.0 to 29.0, with a median of 6.0, which was used as a cutoff. MVC > or = 6.0 was noted in 51% of breast tumors. With increasing tumor size, the higher frequency of positivity of MVC > or = 6.0 (P = .0001), CD44 (P = .001), PRL (P = .002), and c-erb B2 (P = .008), and higher frequency of Bcl-2 negativity (P = .033), was noted. In stage III patients, a higher positivity of the following biomarkers was noted, compared with stage II patients: MVC > or = 6.0 (P = .0004), PRL (P = .0002), c-erb B2 (P = .001), and CD44 (P = .005). Further, Bcl-2 positivity was significantly lower in patients with stage III disease compared with those with stage II disease (P = .024). In patients with nodal involvement, the frequency of c-erb B2 (P = .006), MVC > or = 6.0 (P = .011), and PRL (P = .032) was higher than in those without nodal involvement. Moreover, in these patients, with the increase in the number of involved lymph nodes, there was a significant increase in frequency of CD44+ (P = .0004) and PRL+ (P = .013) tumors. Abnormal expression of one biomarker was seen in 7% of tumors, of two biomarkers in 4%, of three in 15%, of four in 19%, of five in 28%, of six in 20%, and of all seven biomarkers in 7% of tumors. The frequency of an increasing number of biomarkers coexpressed was higher in stage III patients compared with stage II patients (P = .00003). In the total number of patients (n = 93), tumors with Bcl-2 negativity (P = .00001), MVC > or = 6.0 (P = .001), PRL positivity (P = .02), and CD44 positivity (P = .034) had a significantly poorer overall survival (OS) compared with their respective counterparts. In stage II patients (n = 40), only p53 expression was significantly associated with reduced relapse-free survival (P = .009) and OS (P = .040). In multivariate analysis, p53 expression was an independent prognostic factor that influenced relapse-free survival (P = .034) of stage II breast cancer patients. However, it failed to attain statistical significance for OS. In stage III patients (n = 53), tumors with Bcl-2 negativity (P = .0005) and MVC > or = 6.0 (P = .039) had a significantly poorer OS compared with their respective counterparts. In multivariate analysis of stage III patients, Bcl-2 was the only independent prognostic factor (P = .001) for predicting OS. There was a significant association between coexpression of the biomarkers and OS (P = .001). The OS rates decreased with the increase in number of abnormally expressed biomarkers. CONCLUSIONS p53 expression in primary tumors was an independent prognostic factor that influenced relapse-free survival in patients with stage II disease. In stage III patients, lack of Bcl-2 expression was independently associated with a poor prognosis and, thus, may be an indicator of aggressive phenotype.
Collapse
Affiliation(s)
- J M Bhatavdekar
- Department of Cancer Biology, Gujarat Cancer and Research Institute, Ahmedabad, India
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Bhatavdekar JM, Patel DD, Vora HH, Shah NG, Chikhlikar PR, Ghosh N. Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience. Head Neck 2000; 22:257-64. [PMID: 10748449 DOI: 10.1002/(sici)1097-0347(200005)22:3<257::aid-hed8>3.0.co;2-k] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
BACKGROUND The purpose of this study was to assess the role of prolactin (PRL) in men with locally advanced tongue cancer. METHODS Circulating PRL was assayed immunoradiometrically in pretherapeutic and sequential blood samples of 99 patients with locally advanced tongue cancer. Patients were followed for 3 years or until their death within a stipulated time. Immunohistochemical localization of PRL was performed on formalin-fixed paraffin-embedded tissue sections. Tumoral prolactin receptors (PRLR) were estimated by ligand binding assay; the expression of PRL mRNA and PRLR mRNA were carried out by reverse transcriptase polymerase chain reaction (RT-PCR). Furthermore, PRL amplimer was sequenced and compared with human pituitary PRL amplimer. RESULTS Pretherapeutic PRL levels were significantly higher in patients with locally advanced tongue cancer compared with controls (p =.01). Thirty-four percent (34 of 99) of the patients had hyperprolactinemia (PRL >/=15.0 ng/mL). Univariate survival analysis showed that patients with pretherapeutic hyperprolactinemia had a significantly shorter overall survival than patients with pretherapeutic PRL <15.0 ng/mL serum (p =.0009). In multivariate analysis, PRL emerged as the most significant independent prognostic factor influencing overall survival. Furthermore, changes in serial PRL levels showed excellent correlation with response to therapy and progression of disease. Forty-four percent (24 of 54) of the tumors showed positive immunoreactivity with PRL antibody, indicating that PRL or a molecule similar to it is produced by tongue tumors. PRL mRNA expression was seen in 85% (43 of 50) of the tumors and confirmed the de novo synthesis of PRL. Sequence analysis of the 234 bp PRL amplimer revealed that the sequence was homologous to exon 5 of pituitary PRL mRNA. The action of PRL is mediated by PRLR, and it was observed that the PRLR positivity by ligand binding assay was 33%. The expression of PRLR mRNA by RT-PCR showed two forms of PRLR mRNA (ie, intermediate form [500-600 bp] seen in 82% (41 of 50 ) of the tumors and the long form [800-900 bp] seen in 36% (18 of 50) of the tumors. In 82% (41 of 50) of the tumors, either the intermediate or long form was seen. CONCLUSIONS This multifaceted study of PRL suggests that tongue cancer cells produce PRL, and this ectopically produced PRL might be acting as a major local growth promoter by means of autocrine and paracrine mechanisms. Looking at its prognostic value and correlation with disease activity, it may provide new insights into treatment of tongue cancer.
Collapse
Affiliation(s)
- J M Bhatavdekar
- Department of Cancer Biology, The Gujarat Cancer and Research Institute, NCH Compound, Asarwa, Ahmedabad-380 016, India
| | | | | | | | | | | |
Collapse
|
22
|
Wood AJ, Thomas CM, Baumforth KR, Flavell JR, Scott KW, Grace RH, Williams JG, Holland MR, Dunn R, Jacobs AG, Harrison A, Brun S, Plessis N, Murray PG. Absence of prolactin gene expression in colorectal cancer. Mol Pathol 1999; 52:135-9. [PMID: 10621834 PMCID: PMC395687 DOI: 10.1136/mp.52.3.135] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
AIMS Previous studies documenting hyperprolactinaemia in patients with colorectal cancer have suggested that the tumour is the source of hormone production. The aim of this study was to determine the frequency of hyperprolactinaemia in patients with colorectal cancer before, during, and after surgery, and also to determine whether prolactin is produced by these tumours. METHODS Serum prolactin concentrations were measured in 20 patients with colorectal cancer before, during, and after surgical resection of their tumours. Samples taken during surgery included peripheral venous blood and blood taken from the main veins draining the tumour. To determine whether the tumour was responsible for the production of prolactin in these patients, paraffin wax embedded sections of tumour specimens were subjected to immunohistochemistry and western blotting using a monoclonal antibody to prolactin. RESULTS Five patients (three women, two men) had preoperative prolactin concentrations above the normal reference range, although this increase was of clinical importance in only two. After surgical resection of their tumours, prolactin concentrations remained high in both patients. All 20 patients had greatly raised prolactin values at the time of surgery, irrespective of whether this was measured in peripheral blood or in blood taken from veins draining the tumour. All 20 colorectal cancer tissue samples, including those with raised preoperative and/or postoperative prolactin concentrations, were negative for prolactin staining. Frozen tissue was also available in four cases. The absence of prolactin gene expression in these four tumours was confirmed both by repeat immunohistochemistry and by western blotting. A further 50 colorectal cancer cases examined by immunohistochemistry alone were also unreactive for prolactin. CONCLUSIONS The results of this study suggest that serum prolactin concentrations may occasionally be raised in colorectal cancer patients, but that the tumour is not the source of hormone production.
Collapse
Affiliation(s)
- A J Wood
- Department of Pathology, New Cross Hospital, Wolverhampton, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Patel DD, Bhatavdekar JM, Chikhlikar PR, Ghosh N, Suthar TP, Shah NG, Mehta RH, Balar DB. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. J Surg Oncol 1996; 62:86-92. [PMID: 8649046 DOI: 10.1002/(sici)1096-9098(199606)62:2<86::aid-jso3>3.0.co;2-m] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The purpose of this study was to investigate a prognostic indicator that can differentiate node negative breast cancer patients (N = 39, T2N0M0) with high risk and low risk for the development of recurrence or metastases. Preoperative plasma prolactin (PRL) was estimated by radioimmunoassay. The expression of PRL, p53, nm23, and c-erbB2 was investigated by immunohistochemical (IHC) localization; cathepsin D (CD, Enzyme Linked Sorbant Assay) and estrogen- and progesterone-receptors (ER and PR, Dextran coated charcoal method) were estimated in the tumor cytosols. The follow-up period was 2-6 years. Statistical comparisons were made between each marker for relapse-free survival (RFS) and overall survival (OS). Of the 39 patients, 18 had hyperprolactinemia (PRL > 20.0 ng/ml plasma), whereas overexpression of p53 was observed in 55% (17/31) tumors. These were independently and in combination associated with a reduced RFS and OS. The rest of the investigated markers did not show promising results. Hyperprolactinemia and/or overexpression of p53 were associated with aggressiveness of the tumor, early disease relapse or metastases, and poor OS in patients with node negative breast cancer. These two markers may enhance our ability to identify node negative breast cancer patients with aggressive tumors, for whom the use of adjuvant chemo and/or endocrine therapy is unequivocally justified.
Collapse
Affiliation(s)
- D D Patel
- Division of Research, Gujarat Cancer Society, Ahmedabad, India
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Ilan Y, Sibirsky O, Livni N, Gofrit O, Barack V, Goldin E. Plasma and tumor prolactin in colorectal cancer patients. Dig Dis Sci 1995; 40:2010-5. [PMID: 7555457 DOI: 10.1007/bf02208671] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Fifteen consecutive patients with recently diagnosed colorectal cancer were studied for plasma and tumor tissue prolactin content. In eight patients (four men and four postmenopausal females), preoperative high plasmatic prolactin was found (mean 1553 nmol; range 516-3677 nmol). In three of them, prolactin was also present in the tumor cells. All plasma prolactin levels returned to normal after tumor resection and remained so during a three-month follow-up. The tumor stage by Duke distribution was similar for both high and normal plasmatic prolactin patients. The role of prolactin in the pathogenesis of colorectal cancer, and as a marker of the tumor, remains to be established. This is the first time that prolactin has been detected in human colon cancer.
Collapse
Affiliation(s)
- Y Ilan
- Department of Gastroenterology, Hadassah University Hospital, Jerusalem, Israel
| | | | | | | | | | | |
Collapse
|
25
|
Wang DY, Stepniewska KA, Allen DS, Fentiman IS, Bulbrook RD, Kwa HG, De Stavola BL, Reed MJ. Serum prolactin levels and their relationship to survival in women with operable breast cancer. J Clin Epidemiol 1995; 48:959-68. [PMID: 7782804 DOI: 10.1016/0895-4356(94)00201-z] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The prognostic value of serum prolactin levels was assessed in a sequential series of 739 patients who were initially treated at Guy's Hospital, London, between 1975 and 1980. Prolactin was measured in 472 patients 1 day before (Hpr1) and in 457 patients 10 days after (Hpr2) mastectomy. Follow-up of the patients was up to August 1992 giving 6139 women-years with a median follow-up time of 11.5 years (13.7 for patients still living and 5.1 for those dead). The association between the three prolactin variables and reproductive and clinical factors was examined before assessing the prognostic value of prolactin levels in terms of overall, disease-specific and disease-free survival. Multivariate survival models were used in order to adjust for the effect of other prognostic variables. These were found to be: tumour size, degree of nodal involvement, tumour grade and age at diagnosis. The results showed that high Hpr2 or high postoperative increase in prolactin (i.e. Hpr2-Hpr1) were significantly related to shorter disease-specific survival (p = 0.04 and 0.01, respectively) in postmenopausal women. In addition there was some indication, which did not attain formal significance, for this association to occur for disease-free survival. Thus the rise in blood prolactin levels after surgery may be a weak indicator of poor prognosis of breast cancer in postmenopausal women.
Collapse
Affiliation(s)
- D Y Wang
- Unit of Metabolic Medicine, St Mary's Hospital Medical School, London, England
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Cazzaniga M, Lissoni P, Ardizzoia A, Tancini G, Barni S. Influence of presurgical idiopathic hyperprolactinemia on relapse rate in operable breast cancer. Int J Biol Markers 1995; 10:117-8. [PMID: 7561237 DOI: 10.1177/172460089501000210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, Tancini G. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995; 71:854-6. [PMID: 7710954 PMCID: PMC2033724 DOI: 10.1038/bjc.1995.164] [Citation(s) in RCA: 111] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Recent observations have shown that the pineal hormone melatonin (MLT) may modulate oestrogen receptor (ER) expression and inhibit breast cancer cell growth. On this basis, we have evaluated the biological and clinical effects of a concomitant MLT therapy in women with metastatic breast cancer who had progressed in response to tamoxifen (TMX) alone. The study included 14 patients with metastasis who did not respond (n = 3) to therapy with TMX alone or progressed after initial stable disease (SD) (n = 11). MLT was given orally at 20 mg day-1 in the evening, every day starting 7 days before TMX, which was given orally at 20 mg day-1 at noon. A partial response was achieved in 4/14 (28.5%) patients (median duration 8 months). The treatment was well tolerated in all cases, and no MLT-induced enhancement of TMX toxicity was seen; on the contrary, most patients experienced a relief of anxiety. Mean serum levels of insulin-like growth factor 1 (IGF-1), which is a growth factor for breast cancer, significantly decreased on therapy, and this decline was significantly higher in responders than in patients with SD or progression. This pilot phase II study would suggest that the concomitant administration of the pineal hormone MLT may induce objective tumour regressions in metastatic breast cancer patients refractory to TMX alone.
Collapse
Affiliation(s)
- P Lissoni
- Divisione di Radioterapia Oncologica, San Gerardo Hospital, Monza, Milan, Italy
| | | | | | | | | | | | | |
Collapse
|
28
|
Bhatavdekar JM, Patel DD, Vora HH, Shah NG, Karelia NH, Ghosh N, Balar DB. Prolactin: its role in advanced tongue cancer. J Surg Oncol 1994; 57:115-20. [PMID: 7934062 DOI: 10.1002/jso.2930570209] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Serum prolactin was measured pretherapeutically and sequentially thereafter using immunoradiometric assay method in 37 male patients with advanced tongue cancer and compared with 23 healthy, age-matched controls. Prolactin levels were correlated with age, various clinicopathologic parameters, overall survival, and patients with response and those with progressive disease. Patients with advanced tongue cancer had higher prolactin levels than controls (P < 0.02), but intergroup variation in prolactin was not observed when considering the age, site of the lesion, disease stage, histologic grade, and keratin. Of the patients, 30% had hyperprolactinemia (prolactin > 15.0 ng/ml). To assess the prognostic significance of pretherapeutic prolactin level, the patients were divided according to the cutoff level of prolactin (15.0 ng/ml). Hyperprolactinemic patients had more unfavourable prognosis than patients with prolactin < 15.0 ng/ml (X2 = 2.91, df = 1, P < 0.0037). In monitoring disease course, patients who responded to treatments had decreased prolactin levels at the end of 18 months as compared to their pretherapeutic levels (P < 0.01). In patients who subsequently developed progressive disease within 18 months, prolactin levels reduced initially at response, whereas with disease progression, prolactin levels increased significantly (P < 0.05). The positive and negative predictive value of prolactin was 100%. Immunohistochemical localization confirmed the ectopic production of prolactin by tongue tumors. In conclusion, our data indicate that hyperprolactinemia may be an independent predictor of short-term prognosis; circulating prolactin may be used as a marker for monitoring disease course in patients with advanced tongue cancer, and prolactin is produced ectopically by tongue tumors.
Collapse
Affiliation(s)
- J M Bhatavdekar
- Division of Research, Gujarat Cancer Society, Asarwa, Ahmedabad, India
| | | | | | | | | | | | | |
Collapse
|
29
|
Patel DD, Bhatavdekar JM, Ghosh N, Vora HH, Karelia NH, Shah NG, Suthar TP, Balar DB, Trivedi CR. Plasma prolactin in patients with colorectal cancer. Value in follow-up and as a prognosticator. Cancer 1994; 73:570-4. [PMID: 8299078 DOI: 10.1002/1097-0142(19940201)73:3<570::aid-cncr2820730312>3.0.co;2-i] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND Preoperative plasma prolactin and carcinoembryonic antigen (CEA) levels were assessed to monitor disease recurrence and to identify low-risk and high-risk patients with Dukes B or C colorectal cancer. METHODS Prolactin and CEA were estimated by radioimmunoassay method. Blood samples were collected preoperatively and sequentially thereafter from patients with colorectal cancer (N = 114); the samples were compared with samples from age-matched healthy control subjects (smokers and nonsmokers, N = 45). For rest of the analysis, patients with Dukes A disease (N = 7) were not included because of the small number. In monitoring recurrences, the criteria for positive test for the two markers was a continual increase in the marker level after an initial decrease or persistent high level of the marker. These were the indicators of relapse or no response to treatment. To determine the efficacy of the preoperative markers, the patients were grouped according to disease status at the end of 3 years, i.e., patients who had response to the treatment modalities (N = 52) and patients who later had progressive disease (N = 55). To determine the prognostic significance of preoperative marker levels, the patients were divided according to the cutoff levels (upper normal limits); for prolactin the cutoff level was 20.0 ng/ml plasma, and for CEA it was 5.0 ng/ml plasma. RESULTS Both of the markers were significantly high in patients with colorectal cancer compared with the markers of their respective control subjects (P < 0.0001). In monitoring disease course, the predictive power of prolactin was 100%, whereas that of CEA was 66%. Prolactin showed a lead time of 2-3 months. Preoperative prolactin levels were significantly higher in patients who later had progressive disease (P < 0.001) than in patients who had response to the treatments. However, such an intergroup variation was not observed for CEA. Patients with preoperative levels of prolactin greater than 20.0 ng/ml had shorter overall survival times than did those with prolactin levels less than 20.0 ng/ml plasma; such a trend was not observed for patients with CEA levels less than 5.0 ng/ml and those with CEA levels greater than 5.0 ng/ml plasma. CONCLUSION Prolactin is a better overall marker than is CEA in patients with Dukes B or C colorectal cancer. The authors recommend the use of plasma prolactin levels to help identify low-risk and high-risk patient subgroups so that high-risk patients may be followed up more intensely and treated accordingly. Hyperprolactinemic patients with Dukes B or C disease have shortened survival time.
Collapse
Affiliation(s)
- D D Patel
- Division of Research, Gujarat Cancer Society, Asarwa, Ahmedabad, India
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Bhatavdekar JM, Patel DD, Karelia NH, Vora HH, Ghosh N, Shah NG, Balar DB, Trivedi SN. Tumor markers in patients with advanced breast cancer as prognosticators: a preliminary study. Breast Cancer Res Treat 1994; 30:293-7. [PMID: 7981447 DOI: 10.1007/bf00665970] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A retrospective study was performed on 69 breast cancer patients (stage II, N = 18; advanced disease, N = 51) in order to assess the prognostic value of circulating prolactin (PRL), CEA, CA 15-3, insulin-like growth factor-1 (IGF-1), and epidermal growth factor (EGF) by RIA/IRMA. These markers were compared with short-term prognosis (two years). Significant difference was observed only for PRL ( < 20.0 ng/ml vs. > 20.0 ng/ml), which provide an independent predictor of short-term prognosis in advanced breast cancer.
Collapse
Affiliation(s)
- J M Bhatavdekar
- Division of Research, Gujarat Cancer Society, Asarwa, Ahmedabad, India
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Erkişi MK, Burgut R, Unsal M, Ispir T, Varinli S, Kiliçoglu R. Adjuvant use of antiprolactin, antiestrogen, and cytotoxic chemotherapy for breast cancer. Curr Ther Res Clin Exp 1994. [DOI: 10.1016/s0011-393x(05)80078-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
32
|
|
33
|
Bhatavdekar JM, Patel DD, Giri DD, Karelia NH, Vora HH, Ghosh N, Shah NG, Trivedi SN, Balar DB. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. Br J Cancer 1992; 66:977-80. [PMID: 1419646 PMCID: PMC1977975 DOI: 10.1038/bjc.1992.395] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage, histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA levels were significantly higher in colorectal cancer patients than in their respective controls. PRL was elevated in all Dukes stages and in all histological grades of the tumour whereas the rise in CEA was more pronounced in Dukes D. Out of 74 patients, 29% (21/74) developed recurrent disease and 31% (23/74) responded to the treatment. With regard to monitoring recurrence(s), the predictive value of PRL was 94% which was significantly greater than that of CEA which was only 62%. In patients who developed liver metastases PRL remained elevated whereas CEA showed more than 100-fold increase. Therefore, we feel that CEA is a better marker for monitoring patients who developed liver metastases. From our results, we suggest that PRL can be used as a better overall marker for detecting recurrence(s) in patients with colorectal adenocarcinoma.
Collapse
Affiliation(s)
- J M Bhatavdekar
- Division of Research, Gujarat Cancer Society, Asarwa, Ahmedabad, India
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
|
35
|
Marin F, Kovacs KT, Scheithauer BW, Young WF. The pituitary gland in patients with breast carcinoma: a histologic and immunocytochemical study of 125 cases. Mayo Clin Proc 1992; 67:949-56. [PMID: 1434855 DOI: 10.1016/s0025-6196(12)60925-2] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Pituitary glands obtained at autopsy of 125 women with disseminated breast carcinoma were studied to determine whether pituitary prolactin cell abnormalities (hyperplasia or adenoma) might be involved in the pathogenesis of breast carcinoma. In addition, we studied 85 pituitary glands obtained from unselected, consecutive autopsies in women without breast carcinoma but who died of other diseases (control group). The frequency of lactotroph hyperplasia was slightly higher in patients with breast carcinoma than in the control group, but the difference was not statistically significant, nor were differences in the frequency and size of pituitary adenomas, prolactin-producing or otherwise. No correlation was found between the presence of lactotroph hyperplasia or prolactin-producing adenomas (or both) and such factors as the patient's age, bilaterality of the carcinoma, previous treatment with tamoxifen citrate or oophorectomy, stage of disease, or survival. The frequency of breast carcinoma metastatic to the pituitary gland was higher in the study group than in the control group; however, the difference was not statistically significant. No preferential site of metastatic involvement in the pituitary gland was noted. Relative proportions of other lesions such as infarcts, cysts, lymphocytic infiltrates, and basophilic invasion were similar in the study and control groups. This study indicates that accumulation of prolactin cells, whether hyperplastic or adenomatous, cannot be considered a major risk factor for the genesis or progression of breast carcinoma.
Collapse
Affiliation(s)
- F Marin
- Department of Pathology, St. Michael's Hospital, Toronto, Ontario, Canada
| | | | | | | |
Collapse
|
36
|
Barni S, Lissoni P, Mandelli D, Archili C, Real G, Sormani AL, Caprotti R, Tancini G. Relation between Surgery-Induced Prolactin Increase and the Menstrual Cycle Phase at Time of Surgery in Premenopausal Breast Cancer. Int J Biol Markers 1991; 6:103-6. [PMID: 1890313 DOI: 10.1177/172460089100600204] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
It has been suggested that both the menstrual cycle phase and postoperative changes in prolactin (PRL) secretion at the time of surgery may influence the prognosis of breast cancer. The present study was carried out to evaluate the relation between menstrual cycle period and surgery-induced PRL variations. We evaluated 32 premenopausal women with operable breast carcinoma; 17 were in perimenstrual phase (days 1-6 and 21-28) and 15 were in the mid-cycle (days 7-20) period at’ the time of surgery. To investigate serum levels of PRL, venous blood samples were collected before and 7 days after surgery. Postoperative hyperprolactinemia occurred in 17/32 patients and it was statistically more frequent in patients surgically treated during the perimenstrual phase than in the mid-cycle phase (12/17 vs 5/15; p < 0.05), while no other parameter (including axillary node and estrogen receptor status) showed a significant influence on hyperprolactinemia rate. The results suggest that in premenopausal breast cancer patients surgery-induced hyperprolactinemia may be influenced by the menstrual cycle phase at the time of surgery.
Collapse
Affiliation(s)
- S Barni
- Division of Radiation Oncology, San Gerardo Hospital, Monza, Italy
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Lissoni P, Sormani AL, Tancini G, Cattaneo G, Archili C, Mandelli D, Crispino S, Paolorossi F, Barni S. Postoperative hyperprolactinaemia and early recurrence rate in breast cancer. Eur J Cancer 1990; 26:953-6. [PMID: 2149021 DOI: 10.1016/0277-5379(90)90618-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Serum levels of prolactin before and after surgery were measured in 90 women with breast cancer until the 5th postoperative month. Surgery-induced hyperprolactinaemia occurred in 51 patients, without significant correlation to any other clinical variable. After a median follow-up of 39 months, irrespective of each other variable (i.e. nodal involvement, oestrogen receptor status, adjuvant therapies), patients with postoperative hyperprolactinaemia had a significantly lower recurrence rate than those in whom surgery was not followed by an abnormal increase in prolactin secretion (3/51 vs. 13/39, P less than 0.001). These results suggest that, despite the stimulatory role of prolactin on mammary tumours, the lack of postoperative hyperprolactinaemia is an unfavourable prognostic factor because of its association with a higher relapse rate.
Collapse
Affiliation(s)
- P Lissoni
- Division of Radiation Oncology, San Gerardo Hospital, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|